Orally active prostacyclin analogue for cardiovascular disease

International Angiology

Volumn 29, Issue 2 SUPPL. 1, 2010, Pages 14-18

  Nagaya, N ^a,b  

^a Nagaya Cardiovascular and Respiratory Clinic   (Japan)

^b NONE   (Japan)

Author keywords

Analogue; Beraprost; Prostacyclin; Pulmonary hypertension

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BERAPROST; CD34 ANTIGEN; CILOSTAZOL; ILOPROST; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN; SUPEROXIDE; THROMBOXANE; UNIPROST; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ARTERY DISEASE; ATHEROSCLEROSIS; BONE MARROW CELL; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOTAXIS; CONGENITAL HEART DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; ENDARTERECTOMY; FLUSHING; FUNCTIONAL DISEASE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART LUNG TRANSPLANTATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEMODYNAMICS; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LEG PAIN; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REPERFUSION INJURY; REVASCULARIZATION; REVIEW; STEM CELL MOBILIZATION; SURVIVAL; THROMBOCYTE AGGREGATION; VASODILATATION;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; EPOPROSTENOL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77953588449     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
2. Higenbottam TW, Wheeldon D, Wells FC, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;i:1046-7. (Pubitemid 14148935)
3. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301. (Pubitemid 26033085)
4. Belch J, McKay A, McArdle B, Leiberman P, Pollock JG, Lowe GD et al. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983;83:315-7.
5. Sim AK, McCraw AP, Cleland ME, Nishio S, Umetsu T. Effects of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittel-Forsch 1985;35:1816-8.
6. Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium 2: absorption, distribution and excretion after single administration of beraprost sodium in rat. Xenobio Metabol and Dispos 1989;4:101-16.
7. Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H et al. General pharmacology of beraprost sodium, second communication: effects on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimittel-Forsch 1989;39:867-76.
8. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365. (Pubitemid 27197541)
9. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
10. Rubin LJ, Peter RH. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 1980;302:69-73.
11. Rubin LJ, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med 1983;99:433-8.
12. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence of long-term reduction in pulmonary arterial pressure and regression in right ventricular hypertrophy. Circulation 1987;76:135-41. (Pubitemid 17093201)
13. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Resistry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
15. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982;306:557-64.
16. Glanville AR, Burke CM, Theodore J, Robin ED. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 1987;91:675-81.
17. Pasque MK, Trulock EP, Kaiser LD, Cooper JD. Single lung transplantation for pulmonary hypertension: three month hemodynamic follow-up. Circulation 1991;84:2275-9.
18. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
19. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
20. McLaughlin W, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
21. Ichida F, Uese K, Tsubata S, Hashimoto I, Hamamichi Y, Fukahara K et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997;80:662-4.
22. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:188-92.
23. Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
24. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
25. Ono F, Nagaya N, Kyotani S, Oya H, Nakanishi N, Miyatake K. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 2003;67:375-8.
26. Ono F, Nagaya N, Okumura H, Shimizu Y, Kyotani S, Nakanishi N et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003;123:1583-8.
27. Kunieda T, Nakanishi N, Matsubara H, Ohe T, Okano Y, Kondo H et al. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50:513-29.
28. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92.
29. Regensteiner J, Gardner A, Hiatt W. Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status in 1997. Vasc Med 1997;2:147-55.
30. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
31. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP et al. A dose-effect study of beraprost sodium in intermittent claudication. J Card Pharm 1996;27:788-93.
32. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000;102:426-31.
33. Origasa H, Ikeda Y, Shimada K, Shigematsu H. Oral beraprost sodium as a prostaglandin I2 analogue for vascular events in patients with peripheral arterial events in patients with peripheral arterial disease: meta-analysis of two placebo-controlled randomized trials. Jpn J Pharmacoepidemiol 2004;9:45-51.
34. Müller B, Schneider J, Hennies HH, Flohé L. Cardioprotective action of the new stable epoprostenol analogue CG 4203 in rat models of cardiac hypoxia and ischemia. Arzneimittelforschung. 1984;34:1506-9.
35. Nichols WW, Mehta J, Wargovich TJ, Franzini D, Lawson D. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist. Angiology 1989;40:209-21.
36. Kainoh M, Imai R, Nakadake T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990;39:477-83.
37. Ueno Y, Miyauchi Y, Nishio S. Beraprost sodium protects occlusion/reperfusion injury in the dog by inhibition of neutrophil migration. Gen Pharmacol 1994;25:427-32.
38. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
39. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.
40. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 2003;100:12313-8.
41. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001;98:10344-9.
42. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
43. Miyahara Y, Ohnishi S, Obata H, Ishino K, Sano S, Mori H et al. Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006;349:1242-9.
44. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003;107:461-8.